Clearly

Cleerly is a digital health company that leverages artificial intelligence to transform the diagnosis and management of coronary artery disease. Its FDA-cleared platform analyzes non-invasive coronary CT angiography (CCTA) scans to provide a comprehensive, automated assessment of coronary plaque volume and composition. Unlike traditional methods that focus primarily on arterial narrowing (stenosis), Cleerly's technology quantifies and characterizes atherosclerosis to identify at-risk patients earlier and support personalized treatment plans. The company aims to establish a new standard of care for heart disease prevention by providing clinicians with actionable, data-driven insights into cardiac health.